ClinicalTrials.gg
CompletedNCT03069131ProPILARifaxUpdated Apr 10, 2025

Two Strategies of Primary Prophylaxis of Spontaneous Bacterial Peritonitis in Severe Cirrhotic Patients With Ascites

A Phase 3 interventional study of Rifaximin and Placebo in Cirrhosis, Ascites and Peritonitis, sponsored by Centre Hospitalier Universitaire de Besancon. Completed at 18 sites in France. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2025-04-10.

Primary conditionAscitesRegistry: FibrosisReclassifiedWhy we changed it
Registry
Fibrosis — the first condition term the registry derived for this study.
ClinicalTrials.gg
Ascites
Why
  1. Fibrosis is a broad heading, used only when no more specific condition is named.
  2. The study's listed conditions name Ascites.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Centre Hospitalier Universitaire de Besancon · Phase 3, Interventional, and Treatment

Phase
Phase 3
Study type
Interventional
Enrollment
160
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Study summary

We wish to perform a multicenter, double-blind RCT with two parallel-group stratified on the center, comparing rifaximin to no rifaximin (placebo) for the primary prophylaxis of SBP in 'severe' cirrhotic patients with large ascites. The primary outcome will be the 12-month survival.

02

Conditions studied

  • Cirrhosis
  • Ascites
  • Peritonitis

Browse trials for

Keywords

  • primary prophylaxis
  • rifaximin
03

In context

Ascites Reclassified

247 studies on the registry are indexed under Ascites; 57 are open to participants now.

This study's enrollment of 160 is above the median of 54 across 179 interventional studies indexed under Ascites.

Browse Ascites studies →

Lead sponsor

Centre Hospitalier Universitaire de Besancon is the lead sponsor of 450 studies on the registry; 97 are open to participants now.

Compared within Ascites, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Fibrosis. The counts are of registry records indexed under each term, refreshed daily. How we classify →

04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria:

  • Cirrhosis diagnosed on clinical, radiological and/or histological findings
  • Patients with large ascites (i.e., grade 3 ascites requiring paracentesis). Patients with grade 2 ascites are also authorized.
  • Ascites with a low protein level in ascitic fluid (\< 15 g/L) with one of the following three conditions:

    1. impaired renal function defined by serum creatinine ≥ 106 mmol/L, uremia ≥ 9 mmol/L or serum sodium ≤ 130 mmol/L), or
    2. severe liver impairment defined by score ≥ 9 with serum total levels ≥ 51 mmol/L.
    3. severe liver impairment defined by Child-Pugh C
  • Patient who signed an form
  • Patient with a social security system
  • Woman must be surgically sterile or be , or must agree to use effective during the study if .
  • Patients who needs a TIPS if the procedure is performed 3 months or more following the randomization
  • Patients with severe alcoholic hepatitis can be considered for inclusion if the MELD score \< 30 and the Maddrey Discriminant Function \< 60 providing that the patient is not infected (and consequently, will not receive antibiotics) and has not yet received (if necessary). Patients not responding to corticosteroid at day 7 (according to the Lille score) could be include after a of steroids for a period of 7 days.

Exclusion Criteria:

  • Pregnant woman or breastfeeding
  • Vulnerable person regarding french law
  • Individual under legal protection measure
  • Individual unable to exprim his/her consent
  • Person under 18 years of age and over 80 years of age
  • Transplanted patients, infection (or patients who deny HIV serology) or therapy (including patients under corticosteroids for severe alcoholic hepatitis if the patients respond to steroids with improvement of liver function)
  • Patients with a liver transplant project and an estimated waiting time for liver transplantation of 3 months or less
  • Past SBP or any present bacterial infection
  • Patient who have received a TIPS procedure before rhe randomization
  • Patients with an alfapump
  • Patient receiving antibiotics (including rifaximin) in the 7 days preceding the inclusion in this study exept for patients participating to the microbiota study (15 days).
  • to rifaximin, derivatives of rifamycin or one of the constituents of the preparation
  • Hepatocellular carcinoma outside the Milan criteria, other cancer at a palliative stage
  • Any clinical situation with a very low short-terme prognosis (other than cirrhosis), i.e. a survival estimated lower than one month
  • Gastrointestinal bleeding within 7 days
  • Intestinal obstruction
  • Grade 3 hepatic encephalopathy (HE) during the previous 6 months before randomization
  • Chronic heart failure (stage III or IV of the [NYHA] Functional Classification
  • Patient judged as noncompliant
  • Patients who cannot receive a clear information and who have no trusted relatives
  • Patient who refuses the participation agreement by signing the information form and consent as defined in the protocol.
  • Exclusion period from another biomedical study
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
160 participants (actual)

Study arms

  • Experimental
    Active rifaximin

    Drug: Rifaximin

  • Placebo comparator
    Rifaximin placebo

    Other: Placebo

Interventions

  • twice daily administration of 1 tablet containing 550 mg of active rifaximin

  • OtherPlacebo

    twice daily administration of 1 rifaximin placebo tablet

06

What researchers measure

Primary outcomes

  1. death

    record of death whatever the cause

    Time frame: 12 months

Secondary outcomes

  1. Hospital mortality rate and mortality rate at 3 months

    survival during hospitalization and at 3 months

    Time frame: 3 months

  2. Hospital mortality rate and mortality rate at 6 months

    survival during hospitalization and at 6 months

    Time frame: 6 months

  3. Incidence of spontaneous bacterial peritonitis (SBP) during follow-up

    Bacterial analysis of ascites

    Time frame: 12 months

  4. Incidence of the other complications of liver cirrhosis during follow-up

    complications of liver cirrhosis : SBP, HE, gastrointestinal bleeding and hepatorenal syndrome

    Time frame: 12 months

  5. Patient hospitalizations during follow-up

    number of days of hospitalization during 12 months of follow-up

    Time frame: 12 months

  6. Quantitative variations of IL-6 in serum between day 1 and day 30

    Dosage of IL-6 in serum at D1 and D30

    Time frame: 1 month

  7. Quantitative variations of lipopolysaccharides (LPS) in serum between day 1 and day 30

    Dosage of LPS in serum at D1 and D30

    Time frame: 1 month

  8. Quantitative variations of copeptin in serum between day 1 and day 30

    Dosage of copeptin in serum at D1 and D30

    Time frame: 1 month

  9. Quantitative variations of CRP in serum between day 1 and day 30

    Dosage of CRP in serum at D1 and D30

    Time frame: 1 month

  10. Quantitative variations of von Willebrand Factor antigen in serum between day 1 and day 30

    Dosage of von Willebrand Factor antigen in serum at D1 and D30

    Time frame: 1 month

  11. Composition of the intestinal microbiota

    analyzis of microbiota (quantity and quality of main bacterial strains) in 25 patients from arms A and B at day 1, and at months 3, 6, 12 and 18

    Time frame: up to 18 months

  12. Safety analysis of the study drug

    Record of adverse events and serious adverse events in each arm

    Time frame: 12 months

07

Study locations

18 sites
  • CHU Amiens
    Amiens, 80054, France
  • CHU d'Angers
    Angers, France
  • CHU de Besançon
    Besançon, France
  • Hôpital Jean Verdier
    Bondy, France
  • CHU Caen
    Caen, 14033, France
  • Hôpital Beaujon
    Clichy, France
  • CHIC de Créteil
    Créteil, France
  • CHU Grenoble
    La Tronche, 38700, France
  • CHRU de Lille
    Lille, France
  • Hopital de la croix-rousse
    Lyon, 69004, France
  • CHU Montpellier
    Montpellier, 34295, France
  • CHU de Nice
    Nice, France
  • Hôpital Pitié Salpêtrière
    Paris, France
  • CHU de Reims
    Reims, France
  • CHU de Rennes
    Rennes, France
  • CHU Rouen
    Rouen, 76031, France
  • CHU de Toulouse
    Toulouse, France
  • CHU Tours
    Tours, 37044, France
08

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Apr 10, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03069131
Collaborators
Alfasigma S.p.A., LC2 PHARMA
Responsible party
Sponsor
First posted
Mar 3, 2017
Start date
Jun 5, 2018
Primary completion
Jun 3, 2022
Completion
Mar 20, 2023
Last update
Apr 10, 2025

Study contacts

Rodolphe Anty, MD
principal investigator · Centre Hospitalier Universitaire de Nice
Edouard Bardou-Jacquet, MD
principal investigator · Rennes University Hospital
Christophe Bureau, MD, PhD
principal investigator · University Hospital, Toulouse
Vincent Di Martino, MD, PhD
principal investigator · CHRU de Besançon
Claire Francoz, MD
principal investigator · Hôpital Beaujon, Clichy
Alexandra Heurgue-Berlot, MD
principal investigator · CHU de Reims
Marianne Latournerie, MD
principal investigator · Centre Hospitalier Universitaire Dijon
Alexandre Louvet, MD, PhD
principal investigator · CHRU de Lille
Pierre Nahon, MD, PhD
principal investigator · Hôpital Jean Verdier, Bondy
Frédéric Oberti, MD
principal investigator · University Hospital, Angers
Isabelle Rosa-Hezode, MD
principal investigator · CHIC de Créteil
Marika Rudler, MD
principal investigator · Hôpital Pitié-Salpêtrière, APHP
Matthieu Schnee, MD
principal investigator · Hôpital La Roche-sur-Yon
Ghassan Riachi, MD
principal investigator · CHU Rouen
Isabelle Ollivier, MD
principal investigator · CHU Caen
Eric Nguyen-Khac, MD, PhD
principal investigator · CHU Amiens
Laure Elkrief, MD
principal investigator · CHU Tours
Lucy Meunier, MD
principal investigator · University Hospital, Montpellier
Fanny Lebosse, MD
principal investigator · Hopital de la Croix-Rousse
Marie Noelle Hilleret, MD
principal investigator · University Hospital, Grenoble

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Rifaximin

Start the discussion